ACADIA Pharmaceuticals Inc.
ACAD · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $278,633 | $264,566 | $244,317 | $259,602 |
| % Growth | 5.3% | 8.3% | -5.9% | – |
| Cost of Goods Sold | $21,647 | $20,734 | $20,392 | $21,803 |
| Gross Profit | $256,986 | $243,832 | $223,925 | $237,799 |
| % Margin | 92.2% | 92.2% | 91.7% | 91.6% |
| R&D Expenses | $87,829 | $77,951 | $78,265 | $100,731 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $133,401 | $133,507 | $126,370 | $130,080 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | -$146,515 |
| Operating Expenses | $221,230 | $211,458 | $204,635 | $84,296 |
| Operating Income | $35,756 | $32,374 | $19,290 | $153,503 |
| % Margin | 12.8% | 12.2% | 7.9% | 59.1% |
| Other Income/Exp. Net | $8,839 | $7,837 | $8,489 | $7,582 |
| Pre-Tax Income | $44,595 | $40,211 | $27,779 | $161,085 |
| Tax Expense | -$27,184 | $13,545 | $8,792 | $17,343 |
| Net Income | $71,779 | $26,666 | $18,987 | $143,742 |
| % Margin | 25.8% | 10.1% | 7.8% | 55.4% |
| EPS | 0.43 | 0.16 | 0.11 | 0.87 |
| % Growth | 168.8% | 45.5% | -87.4% | – |
| EPS Diluted | 0.42 | 0.16 | 0.11 | 0.86 |
| Weighted Avg Shares Out | 168,836 | 167,827 | 166,808 | 166,535 |
| Weighted Avg Shares Out Dil | 170,650 | 168,681 | 167,668 | 166,362 |
| Supplemental Information | – | – | – | – |
| Interest Income | $8,246 | $7,243 | $7,901 | $7,007 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $2,950 | $2,935 | $2,951 | $5,214 |
| EBITDA | $47,545 | $35,309 | $22,241 | $12,202 |
| % Margin | 17.1% | 13.3% | 9.1% | 4.7% |